Downregulation of BMI-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells

Biochemical and Biophysical Research Communications

Volumn 371, Issue 3, 2008, Pages 531-535

  Qin, Li ^a,b,c   Zhang, Xing ^b   Zhang, Ling ^b   Feng, Yan ^b   Weng, Gui Xiang ^b   Li, Man Zhi ^b   Kong, Qing Li ^b   Qian, Chao Nan ^b   Zeng, Yi Xin ^b   Zeng, Mu Sheng ^b   Liao, Duan Fang ^a,c   Song, Li Bing ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Apoptosis; BMI 1; Chemotherapy; Nasopharyngeal carcinoma

Indexed keywords

BMI1 PROTEIN; FLUOROURACIL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; RNA;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CHEMOSENSITIVITY; DOWN REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; STATISTICAL SIGNIFICANCE; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; MICRORNAS; NASOPHARYNGEAL NEOPLASMS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; REPRESSOR PROTEINS; RNA INTERFERENCE; TRANSFECTION;

MOLONEY MURINE LEUKEMIA VIRUS;

EID: 43549102626     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.04.117     Document Type: Article

References (28)

1. Lo K.W., and Huang D.P. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin. Cancer Biol. 12 (2002) 451-462
2. Cheung S.T., Huang D.P., Hui A.B., Lo K.W., Ko C.W., Tsang Y.S., Wong N., Whitney B.M., and Lee J.C. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int. J. Cancer 83 (1999) 121-126
3. Wu Y.T., Wang H.M., Yang X.P., Li M.Z., Chen J., Fang Y., et al. Establishment and characterization of a xenografted nasopharyngeal carcinoma and corresponding epithelial cell line. Ai Zheng 14 (1995) 83-86
4. Chan A.T., Leung S.F., Ngan R.K., Teo P.M., Lau W.H., Kwan W.H., et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J. Natl. Cancer Inst. 97 (2005) 536-539
5. Lin J.C., Jan J.S., Hsu C.Y., Liang W.M., Jiang R.S., and Wang W.Y. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J. Clin. Oncol. 21 (2003) 631-637
6. Wee J., Tan E.H., Tai B.C., Wong H.B., Leong S.S., Tan T., et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J. Clin. Oncol. 23 (2005) 6730-6738
7. Valk-Lingbeek M.E., Bruggeman S.W., and van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 118 (2004) 409-418
8. Haupt Y., Alexander W.S., Barri G., Klinken S.P., and Adams J.M. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 65 (1991) 753-763
9. van Lohuizen M., Verbeek S., Scheijen B., Wientjens E., van der Gulden H., and Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65 (1991) 737-752
10. van der Lugt N.M., Domen J., Linders K., van Roon M., Robanus-Maandag E., te Riele H., et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 8 (1994) 757-769
11. Pirrotta V. Polycombing the genome: PcG, trxG, and chromatin silencing. Cell 93 (1998) 333-336
12. Leung C., Lingbeek M., and Shakhova O. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428 (2004) 337-341
13. Vonlanthen S., Heighway J., Altermatt H.J., Gugger M., Kappeler A., Borner M.M., et al. The bmi-1 oncoprotein is differentially expressed in nonsmall cell lung cancer and correlates with INK4A-ARF locus expression. Br. J. Cancer 84 (2001) 1372-1376
14. Kim J.H., Yoon S.Y., Kim C.N., Joo J.H., Moon S.K., Choe I.S., et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/ p14ARF proteins. Cancer Lett. 203 (2004) 217-224
15. Kang M.K., Kim R.H., Kim S.J., Yip F.K., Shin K.H., Dimri G.P., et al. Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br. J. Cancer 96 (2007) 126-133
16. Song L.B., Zeng M.S., Liao W.T., Zhang L., Mo H.Y., Liu W.L., et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 66 (2006) 6225-6232
17. Hannon G.J. RNA interference. Nature 418 (2002) 244-251
18. Liu L., Andrews L.G., and Tollefsbol T.O. Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death. Oncogene 25 (2006) 4370-4375
19. Guo W.J., Datta S., Band V., and Dimri G.P. Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins. Mol. Biol. Cell 18 (2007) 536-546
20. Song L.B., Liao W.T., Mai H.Q., Zhang H.Z., Zhang L., Li M.Z., et al. The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett. 242 (2006) 257-264
21. Mader R.M., Müller M., and Steger G.G. Resistance to 5-fluorouracil. Gen. Pharmacol. 31 (1998) 661-666
22. Lee K., Adhikary G., Balasubramanian S., Gopalakrishnan R., McCormick T., Dimri G.P., Eckert R.L., and Rorke E.A. Expression of Bmi-1 in epidermis enhances cell survival by altering cell cycle regulatory protein expression and inhibiting apoptosis. J. Invest. Dermatol. 128 (2008) 9-17
23. Chaudhary K.S., Abel P.D., Stamp G.W., and Lalani E. Differential expression of cell death regulators in response to thapsigargin and adriamycin in Bcl-2 transfected DU145 prostatic cancer cells. J. Pathol. 193 (2001) 522-529
24. Oltvai Z.N., Milliman C.L., and Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74 (1993) 609-619
25. Sun Y., Hegamyer G., Cheng Y.J., Hildesheim A., Chen J.Y., Chen I.H., Cao Y., et al. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc. Natl. Acad. Sci. USA 89 (1992) 6516-6520
26. Clark A.S., West K., Streicher S., and Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 1 (2002) 707-717
27. Hu L., Hofmann J., Lu Y., Mills G.B., and Jaff R.B. Inhibition of phosphatidylinositol 3V-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 62 (2002) 1087-1092
28. Guo W.J., Zeng M.S., Yadav A., Song L.B., Guo B.H., Band V., et al. Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res. 67 (2007) 5083-5089